1887

Abstract

Huangqin Decoction (HQD), a Chinese herbal formula, is widely used for various diseases, including colorectal cancer (CRC).

We proposed that microbial butyrate mediated PI3K/Akt pathway suppression might involve the anti-cancer effect of HQD.

This study aimed to evaluate the potential mechanism of HQD against CRC.

An azoxymethane plus dextran sulphate sodium induced CRC mouse model was used, and the intestinal flora and faecal short-chain fatty acid changes were detected, respectively, after HQD administration with 16S rRNA sequencing and gas chromatography coupled with mass spectrometry. Disease activity index, colon length and levels of inflammatory cytokines were measured to evaluate the effect of HQD on intestinal inflammation. Tumour size, number and histopathology were assessed to reflect the impact of HQD on tumour burden. Apoptosis and PI3K/Akt pathway activity were measured by TUNEL staining and Western-blotting. , the effects of sodium butyrate (NaB) on the viability of CRC cell lines were detected by the Cell-counting Kit-8. The apoptotic cells were determined by TUNEL staining. Cell migration and invasion were assessed by wound healing assay and Transwell assay, respectively. Western-blotting and immunofluorescent staining were used to test the activity of PI3K/Akt pathway.

Animal study showed that HQD could improve the gut dysbiosis, increase the abundance of and the level of faecal butyric acid. Then, we found that HQD could attenuate colitis, reduce tumour burden, promote cell apoptosis and suppress PI3K/Akt pathway activity in CRC mice. experiment revealed that NaB treatment could inhibit cell growth, migration and invasion in CRC cell lines. Additionally, NaB enhanced cellular apoptosis, and reduced phosphorylated PI3K and Akt expressions. Interestingly, addition of 740Y-P, an agonist of PI3K, reversed the NaB effects on CRC cells.

Overall, in this study, we revealed that HQD could induce apoptosis through microbial butyrate mediated PI3K/Akt inhibition and perform anti-CRC activity.

Funding
This study was supported by the:
  • Zhejiang Traditional Chinese Medicine Science and Technology Project (Award 2020ZA044)
    • Principle Award Recipient: Bao-YingFei
  • 13th Five-Year Plan of Zhejiang Provincial Key Discipline Construction of Traditional Chinese Medicine (Award 2017-XK-B02)
    • Principle Award Recipient: FeiBao-Ying
  • National Natural Science Foundation of China (Award 82004333)
    • Principle Award Recipient: Jia-JieZhu
  • Natural Science Foundation of Zhejiang Province (Award LQ21H290002)
    • Principle Award Recipient: Jia-JieZhu
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001692
2023-05-17
2024-12-05
Loading full text...

Full text loading...

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71:209–249 [View Article] [PubMed]
    [Google Scholar]
  2. Wei W, Zeng H, Zheng R, Zhang S, An L et al. Cancer registration in China and its role in cancer prevention and control. Lancet Oncol 2020; 21:e342–e349 [View Article] [PubMed]
    [Google Scholar]
  3. Xia C, Dong X, Li H, Cao M, Sun D et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J 2022; 135:584–590 [View Article] [PubMed]
    [Google Scholar]
  4. Yothers G, Sargent DJ, Wolmark N, Goldberg RM, O’Connell MJ et al. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. J Natl Cancer Inst 2011; 103:1498–1506 [View Article] [PubMed]
    [Google Scholar]
  5. Nalli M, Puxeddu M, La Regina G, Gianni S, Silvestri R. Emerging therapeutic agents for colorectal cancer. Molecules 2021; 26:7463 [View Article] [PubMed]
    [Google Scholar]
  6. Motta R, Cabezas-Camarero S, Torres-Mattos C, Riquelme A, Calle A et al. Personalizing first-line treatment in advanced colorectal cancer: present status and future perspectives. J Clin Transl Res 2021; 7:771–785 [PubMed]
    [Google Scholar]
  7. Blondy S, David V, Verdier M, Mathonnet M, Perraud A et al. 5-Fluorouracil resistance mechanisms in colorectal cancer: from classical pathways to promising processes. Cancer Sci 2020; 111:3142–3154 [View Article] [PubMed]
    [Google Scholar]
  8. Tabernero J, Velez L, Trevino TL, Grothey A, Yaeger R et al. Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study. ESMO Open 2021; 6:100328 [View Article] [PubMed]
    [Google Scholar]
  9. Lee GY, Lee JS, Son CG, Lee NH. Combating drug resistance in colorectal cancer using herbal medicines. Chin J Integr Med 2021; 27:551–560 [View Article] [PubMed]
    [Google Scholar]
  10. Kong MY, Li LY, Lou YM, Chi HY, Wu JJ. Chinese herbal medicines for prevention and treatment of colorectal cancer: from molecular mechanisms to potential clinical applications. J Integr Med 2020; 18:369–384 [View Article] [PubMed]
    [Google Scholar]
  11. Wang X, Cui D-N, Dai X-M, Wang J, Zhang W et al. HuangQin decoction attenuates CPT-11-induced gastrointestinal toxicity by regulating bile acids metabolism homeostasis. Front Pharmacol 2017; 8:156 [View Article] [PubMed]
    [Google Scholar]
  12. Xing S, Wang Y, Hu K, Wang F, Sun T et al. WGCNA reveals key gene modules regulated by the combined treatment of colon cancer with PHY906 and CPT11. Biosci Rep 2020; 40:BSR20200935 [View Article] [PubMed]
    [Google Scholar]
  13. Zhang W, Saif MW, Dutschman GE, Li X, Lam W et al. Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS). J Chromatogr A 2010; 1217:5785–5793 [View Article] [PubMed]
    [Google Scholar]
  14. Farrell MP, Kummar S. Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer. Clin Colorectal Cancer 2003; 2:253–256 [View Article] [PubMed]
    [Google Scholar]
  15. Lam W, Bussom S, Guan F, Jiang Z, Zhang W et al. The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Sci Transl Med 2010; 2:45ra59 [View Article] [PubMed]
    [Google Scholar]
  16. Xu D-D, Hou X-Y, Wang O, Wang D, Li D-T et al. A four-component combination derived from Huang-Qin Decoction significantly enhances anticancer activity of irinotecan. Chin J Nat Med 2021; 19:364–375 [View Article] [PubMed]
    [Google Scholar]
  17. Lam W, Jiang Z, Guan F, Huang X, Hu R et al. PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment. Sci Rep 2015; 5:9384 [View Article] [PubMed]
    [Google Scholar]
  18. Li M-Y, Luo H-J, Wu X, Liu Y-H, Gan Y-X et al. Anti-inflammatory effects of Huangqin decoction on dextran sulfate sodium-induced ulcerative colitis in mice through regulation of the gut microbiota and suppression of the Ras-PI3K-Akt-HIF-1α and NF-κB pathways. Front Pharmacol 2019; 10:1552 [View Article] [PubMed]
    [Google Scholar]
  19. Prossomariti A, Piazzi G, Alquati C, Ricciardiello L. Are Wnt/β-Catenin and PI3K/AKT/mTORC1 distinct pathways in colorectal cancer?. Cell Mol Gastroenterol Hepatol 2020; 10:491–506 [View Article] [PubMed]
    [Google Scholar]
  20. Jiang T, Wang H, Liu L, Song H, Zhang Y et al. CircIL4R activates the PI3K/AKT signaling pathway via the miR-761/TRIM29/PHLPP1 axis and promotes proliferation and metastasis in colorectal cancer. Mol Cancer 2021; 20:167 [View Article] [PubMed]
    [Google Scholar]
  21. Cheng Y, Wang G, Zhao L, Dai S, Han J et al. Periplocymarin induced colorectal cancer cells apoptosis via impairing PI3K/AKT pathway. Front Oncol 2021; 11:753598 [View Article] [PubMed]
    [Google Scholar]
  22. Wu J, Li Q, Fu X. Fusobacterium nucleatum contributes to the carcinogenesis of colorectal cancer by inducing inflammation and suppressing host immunity. Transl Oncol 2019; 12:846–851 [View Article] [PubMed]
    [Google Scholar]
  23. Chang S-C, Shen M-H, Liu C-Y, Pu C-M, Hu J-M et al. A gut butyrate-producing bacterium Butyricicoccus pullicaecorum regulates short-chain fatty acid transporter and receptor to reduce the progression of 1,2-dimethylhydrazine-associated colorectal cancer. Oncol Lett 2020; 20:327 [View Article] [PubMed]
    [Google Scholar]
  24. Kim HJ, An J, Ha EM. Lactobacillus plantarum-derived metabolites sensitize the tumor-suppressive effects of butyrate by regulating the functional expression of SMCT1 in 5-FU-resistant colorectal cancer cells. J Microbiol 2022; 60:100–117 [View Article] [PubMed]
    [Google Scholar]
  25. Soltan Dallal MM, Mojarrad M, Baghbani F, Raoofian R, Mardaneh J et al. Effects of probiotic Lactobacillus acidophilus and Lactobacillus casei on colorectal tumor cells activity (CaCo-2). Arch Iran Med 2015; 18:167–172 [PubMed]
    [Google Scholar]
  26. Yin B, Liu H, Tan B, Dong X, Chi S et al. Dietary supplementation of β-conglycinin, with or without sodium butyrate on the growth, immune response and intestinal health of hybrid grouper. Sci Rep 2021; 11:17298 [View Article] [PubMed]
    [Google Scholar]
  27. Huang S, He J, Chen Y, Wang X, Li Y et al. Effect of Huangqin decoction on regulating intestinal flora in colitis mice characterized as inhibition of the NOD2-dependent pathway. Pharm Biol 2022; 60:108–118 [View Article] [PubMed]
    [Google Scholar]
  28. Arnesen H, Müller MHB, Aleksandersen M, Østby GC, Carlsen H et al. Induction of colorectal carcinogenesis in the C57BL/6J and A/J mouse strains with a reduced DSS dose in the AOM/DSS model. Lab Anim Res 2021; 37:19 [View Article] [PubMed]
    [Google Scholar]
  29. Neufert C, Becker C, Neurath MF. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat Protoc 2007; 2:1998–2004 [View Article] [PubMed]
    [Google Scholar]
  30. Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S et al. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci 2003; 94:965–973 [View Article] [PubMed]
    [Google Scholar]
  31. Chen G, Yang Y, Hu C, Cheng X, Xu Y et al. Protective effects of Huangqin Decoction against ulcerative colitis and associated cancer in mice. Oncotarget 2016; 7:61643–61655 [View Article] [PubMed]
    [Google Scholar]
  32. Tian Y, Xu Q, Sun LQ, Ye Y, Ji GZ. Short-chain fatty acids administration is protective in colitis-associated colorectal cancer development. J Nutr Biochem 2018; 57:103–109 [View Article] [PubMed]
    [Google Scholar]
  33. Shi H, Tian S, Tian H. Network pharmacology interpretation of Fuzheng-Jiedu decoction against colorectal cancer. Evid Based Complement Alternat Med 2021; 2021:4652492 [View Article] [PubMed]
    [Google Scholar]
  34. Li Z, Feiyue Z, Gaofeng L. Traditional Chinese medicine and lung cancer--From theory to practice. Biomed Pharmacother 2021; 137:111381 [View Article] [PubMed]
    [Google Scholar]
  35. Han Y, Wang H, Xu W, Cao B, Han L et al. Chinese herbal medicine as maintenance therapy for improving the quality of life for advanced non-small cell lung cancer patients. Complement Ther Med 2016; 24:81–89 [View Article] [PubMed]
    [Google Scholar]
  36. Human Microbiome Project Consortium Structure, function and diversity of the healthy human microbiome. Nature 2012; 486:207–214 [View Article] [PubMed]
    [Google Scholar]
  37. Chen Y-Z, Yuan M-Y, Chen YL, Zhang X, Xu X-T et al. The gut microbiota and traditional Chinese medicine: a new clinical frontier on cancer. Curr Drug Targets 2021; 22:1222–1231 [View Article] [PubMed]
    [Google Scholar]
  38. Aprile F, Bruno G, Palma R, Mascellino MT, Panetta C et al. Microbiota alterations in precancerous colon lesions: a systematic review. Cancers 2021; 13:3061 [View Article] [PubMed]
    [Google Scholar]
  39. Choi S, Chung J, Cho ML, Park D, Choi SS. Analysis of changes in microbiome compositions related to the prognosis of colorectal cancer patients based on tissue-derived 16S rRNA sequences. J Transl Med 2021; 19:485 [View Article] [PubMed]
    [Google Scholar]
  40. Niccolai E, Russo E, Baldi S, Ricci F, Nannini G et al. Significant and conflicting correlation of IL-9 with Prevotella and Bacteroides in human colorectal cancer. Front Immunol 2021; 11:573158 [View Article]
    [Google Scholar]
  41. Peters BA, Dominianni C, Shapiro JA, Church TR, Wu J et al. The gut microbiota in conventional and serrated precursors of colorectal cancer. Microbiome 2016; 4:69 [View Article] [PubMed]
    [Google Scholar]
  42. Park CH, Eun CS, Han DS. Intestinal microbiota, chronic inflammation, and colorectal cancer. Intest Res 2018; 16:338–345 [View Article] [PubMed]
    [Google Scholar]
  43. Wang T, Cai G, Qiu Y, Fei N, Zhang M et al. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J 2012; 6:320–329 [View Article] [PubMed]
    [Google Scholar]
  44. Mirzaei R, Dehkhodaie E, Bouzari B, Rahimi M, Gholestani A et al. Dual role of microbiota-derived short-chain fatty acids on host and pathogen. Biomed Pharmacother 2022; 145:112352 [View Article] [PubMed]
    [Google Scholar]
  45. Alvandi E, Wong WKM, Joglekar MV, Spring KJ, Hardikar AA. Short-chain fatty acid concentrations in the incidence and risk-stratification of colorectal cancer: a systematic review and meta-analysis. BMC Med 2022; 20:323 [View Article] [PubMed]
    [Google Scholar]
  46. Yu T, Ji L, Lou L, Ye S, Fang X et al. Fusobacterium nucleatum affects cell apoptosis by regulating intestinal flora and metabolites to promote the development of colorectal cancer. Front Microbiol 2022; 13:841157 [View Article] [PubMed]
    [Google Scholar]
  47. Giuliano M, Pellerito C, Celesia A, Fiore T, Emanuele S. Tributyltin(IV) butyrate: a novel epigenetic modifier with ER stress- and apoptosis-inducing properties in colon cancer cells. Molecules 2021; 26:16 [View Article] [PubMed]
    [Google Scholar]
  48. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013; 341:569–573 [View Article] [PubMed]
    [Google Scholar]
  49. Qiao C-M, Sun M-F, Jia X-B, Shi Y, Zhang B-P et al. Sodium butyrate causes α-synuclein degradation by an Atg5-dependent and PI3K/Akt/mTOR-related autophagy pathway. Exp Cell Res 2020; 387:111772 [View Article] [PubMed]
    [Google Scholar]
  50. Chen G, Ran X, Li B, Li Y, He D et al. Sodium butyrate inhibits inflammation and maintains epithelium barrier integrity in a TNBS-induced inflammatory bowel disease mice model. EBioMedicine 2018; 30:317–325 [View Article] [PubMed]
    [Google Scholar]
  51. He X-S, Ye W-L, Zhang Y-J, Yang X-Q, Liu F et al. Oncogenic potential of BEST4 in colorectal cancer via activation of PI3K/Akt signaling. Oncogene 2022; 41:1166–1177 [View Article] [PubMed]
    [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.001692
Loading
/content/journal/jmm/10.1099/jmm.0.001692
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error